Arcus Biosciences, Inc.
RCUSArcus Biosciences, Inc. is a clinical-stage immuno-oncology company focused on developing innovative cancer therapies. The company specializes in programmed cell death and immune modulation, leveraging its proprietary tumor microenvironment expertise to create targeted treatments aimed at improving patient outcomes in solid tumors and hematologic cancers.
Company News
Juan C. Jaen, president of Arcus Biosciences, sold 68,569 shares for $2.0 million through a trust under a Rule 10b5-1 trading plan, while maintaining ~1.2 million shares. The sale appears motivated by tax and liquidity management following a 200% stock surge. Arcus has refocused on casdatifan, its HIF-2α kidney cancer drug, after discontinuing a...
The article discusses the global surge in cancer cases, particularly among people under 50, and the efforts of biotech companies to develop new therapies to combat this trend. It highlights recent progress and upcoming studies from several companies in the oncology space.
The global retinoblastoma treatment market is projected to grow from $1.93 billion in 2023 to $2.03 billion in 2024, driven by factors like increased funding, cancer research, and technological advancements. The market is expected to reach $2.56 billion by 2028, growing at a CAGR of 5.9%.
Arcus Biosciences (RCUS) underwent analysis by 4 analysts in the last quarter, with a downward trend in their 12-month price targets. The article provides a detailed breakdown of the analysts' recent evaluations, ratings, and price targets for the company.
Investors need to pay close attention to Arcus Biosciences (RCUS) stock based on the movements in the options market lately.